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Abstract
Although protein Z (PZ) has a domain arrangement similar to the essential coagulation proteins FVII, FIX,
FX, and protein C, its serine protease (SP)-like domain is incomplete and does not exhibit proteolytic
activity. We have generated a trial sequence of putative activated protein Z (PZa) by identifying amino acid
mutations in the SP-like domain that might reasonably resurrect the serine protease catalytic activity of PZ.
The structure of the activated form was then modeled based on the proposed sequence using homology
modeling and solvent-equilibrated molecular dynamics simulations. In silico docking of inhibitors of
FVIIa and FXa to the putative active site of equilibrated PZa, along with structural comparison with its
homologous proteins, suggest that the designed PZa can possibly act as a serine protease.
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Protein Z (PZ) is a vitamin K-dependent (VKD) protein
relatively abundant in humans, with a wide plasma
concentration range (Miletich and Broze Jr. 1987). PZ
circulates in plasma as a complex with protein Z-dependent
protease inhibitor (ZPI) (Tabatabai et al. 2001). The most
important known physiological function of PZ is its ability
to enhance the inhibition of factor Xa by ZPI 1000-fold in
the presence of phospholipid membrane and Ca2+ ions (Han
et al. 1998; Al-Shanqeeti et al. 2005).
PZ is homologous to coagulation factors FVII, FIX, FX,
and protein C (PC), and the domain assembly of PZ is
identical to these proteins. It is composed of four domains:
an N-terminal Gla domain, two epidermal growth factor
(EGF)-like domains (EGF1 and EGF2 domains), and a
serine protease (SP)-like domain (Ichinose et al. 1990;
Sejima et al. 1990). However, PZ lacks the critical histidine
and serine residues of the catalytic triad, and is therefore not a
zymogen of a serine protease. Based on its homology with the
other coagulation factors, we proposed a solvent-equilibrated
model of human PZ using comparative modeling and
molecular dynamics (MD) simulation (Lee et al. 2007).
One of the striking features in this model was that even
though PZ lacked two of the critical catalytic triad residues,
the relative spatial arrangement of the putative active site
region and the distances between these residues were similar
to the other serine proteases after a long time simulation.
The two b-barrel domains in PZ were juxtaposed similar to
other chymotrypsin-like enzymes, even without an active
catalytic triad bridging them. In addition, the residues
Met309 and Val331, which correspond to a disulfide bond
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(Cys191–Cys220, chymotrypsinogen numbering) in other
VKD SP domains, were close to disulfide bond-forming
distance without distance or position constraints imposed.
These observations raised questions about the evolution of
PZ and led us to consider if PZ could have once been func-
tionally active as a serine protease. Studies on serine protease
evolution have shown that apart from protease domain
sequences, the development and maintenance of the active
site structure plays an important role in the evolution of
proteolytic enzymes (Krem and Di Cera 2001, 2002). The
preservation of the active site three-dimensional (3D) struc-
ture in PZ compared with other serine proteases indicates the
operation of a possible divergent evolution mechanism
within this structural family and raises the question of
whether an active PZ was disfavored in evolution through
sequence mutations in the protease domain. A possible
reason for this evolutionary choice may have been due to
negative evolutionary pressure brought about by undesirable
function. Another possibility is that PZ might have been an
ancestor of FVII, FIX, FX, and PC. This possibility, however,
seems unlikely based on genomic evidence from a recent
study that characterized blood coagulation proteins (using
new genetic databases) in a jawless vertebrate system (lam-
prey) (Doolittle et al. 2008). It was found that homologs for
FVII, FIX, FX, and PC exist in jawless vertebrates, whereas
no matches are found for PZ. The earliest homolog of PZ is
found only in jawed vertebrates like fugu and zebrafish,
which indicates that PZ evolved later than the other coagu-
lation serine proteases (Davidson et al. 2003).
In order to understand the evolutionary significance, it
is desirable to model the 3D structure of the putative
activated form of PZ (PZa). Apart from the evolutionary
aspect, this in silico model building is also interesting as a
protein design challenge to generate an activated form of
a serine protease starting from an inactive form. A recent
experimental work (Ortlund et al. 2007) has shown that it
is possible to resurrect an ancestral protein by employing
evolutionary relationship to sequence comparisons, dra-
matically leading to the X-ray crystal structure.
Given our 3D model for protein Z, an in silico PZa model
was constructed by designing a primary sequence of PZa
that might reasonably resurrect serine protease catalytic
activity and then simulating a 3D solvent-equilibrated
structure of the activated form. Further, a molecular
docking study was employed to partially validate the
predicted model by evaluating its ability to bind in silico
to known serine protease inhibitors for FVIIa and FXa.
Results and Discussion
Model building
The proposed sequence of PZa has 36%–39% amino acid
identities in the SP domain with the four structural
templates used for model building (Fig. 1). This sequence
identity is a substantial improvement from the PZ sequence
for the SP domain (with all the active site residues con-
served) and therefore offers a reasonable starting point for
homology modeling. The root mean square deviations
(RMSD) of the backbone atoms for our initial PZa model
with the crystal structure of FVIIa (1DAN) and FXa
(1XKA) in the SP domain were 0.93 and 0.73 Å for 824
and 868 atoms, respectively, using the program Swiss-
PdbViewer (Guex and Peitsch 1997), while the correspond-
ing value for FVIIa with FXa was 0.96 Å over 860
atoms. PROCHECK was used to calculate the f-c angles
for the Ramachandran plot, which shows that most of the
f-c angles (85.9%) are located in the core region of the
plot, and only 0.3% were in the disallowed region
(Supplemental Fig. S1). The bad contacts (steric clashes)
present in the initial homology model have been elimi-
nated after the MD simulation. The PZa model was also
assessed using the Verify3D algorithm, and the 3D to 1D
scores of our model are always positive (a criterion of
proper folding) and are similar to those obtained with the
template structures of FVIIa and FXa (Supplemental Fig.
S2). The disulfide bonds were modeled based on homol-
ogy with FVII, FIX, FX, and PC. In PZ (and in the PZa
model), there is a possibility of an additional disulfide
bond between residues Cys131 in the EGF2 domain and
Cys234 in the SP domain (G.J. Broze, pers. comm.). After
11 ns of MD simulation, the Ca–Ca distance between
these residues is 8.82 Å. Since these residues are present
in nearby loop regions, there is a possibility that these
cysteines could also be involved in disulfide bonding. We
have not modeled in this disulfide in this work, since it does
not appear in the other four homologs, although it repre-
sents a consideration in future work.
Structural features of PZa
The objective of our study was to propose a reasonable
sequence for an active PZ and to model the 3D structure
of the active form based on the proposed sequence.
Additionally, we wished to examine our equilibrated
structure of the activated form for similarities with other
active blood coagulation factors.
A plot of the backbone RMSD relative to the initial
structure over 19 ns of MD simulation (Supplemental Fig.
S3) shows that the model has equilibrated. Inspection of
the final structures showed no bad contacts among
residues. As expected, the model shows structural proper-
ties characteristic of the blood coagulation serine protease
family and is structurally similar to FVIIa, FXa, and other
serine proteases. The equilibrated structure of this protein
reveals the presence of a His–Asp–Ser catalytic triad
arrangement similar to that of other serine proteases. The
H-bonding between His57 and Ser195 was, however,
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intermittent compared with other serine proteases, present
only for ;28% of over 7.5 ns of simulation time. A sep-
arate simulation of FVIIa using a comparable simulation
protocol showed that the His57–Ser195 H-bonding was
present for ;60% of the simulation time. So, the H-bonding
was intermittent in both the proteins, but was present
relatively longer in FVIIa. The topology of the substrate-
binding site adjacent to the catalytic triad is well preserved
after a long time simulation. In PZa, the overall topology of
the active site is similar to that of other serine proteases, as a
majority of the binding site residues are conserved after
sequence modification. The substitutions of Met191 and
Val220 with Cys and the formation of a disulfide bond
between these cysteine residues helped maintain an S1
specificity pocket in the PZa structure. The overall spatial
architecture of the S1 pocket, which is built of two b-strands
(residues 214–216, 226–228), loop residues 189–192, and
the oxyanion hole (Gly193 and Ser195), is similar to other
blood coagulation serine proteases. There are differences,
however, in the distant structural elements that are often the
determinants of S1 specificity and might lead to different
ligand specificity. It was also observed from our simula-
tion that the S1 site Asp189 residue forms a salt bridge
interaction with Arg158, which causes a change in orienta-
tion of the Asp189 side chain in PZa compared with FVIIa
and FXa, for which there is a Leu in place of Arg. We have
carried out docking of known FVIIa and FXa inhibitors
(below) to examine if the overall topology of the PZa active
site region is similar to other blood coagulation serine
proteases and also to study differences that might confer
specificity to putative PZa.
An unrestrained simulation of the modeled PZa
revealed a bend in the structure of PZa in the N-terminal
region of the EGF2 domain (Fig. 2A), which brings the
orientation of the SP domain close to the EGF1 domain.
This bend was also observed in our previous extended
Figure 1. Multiple sequence alignment of PZ with human FVIIa, FIXa, FXa, and PC. The PZa sequence in the alignment shows
modifications of PZ to obtain the sequence of the activated form. The sequence modifications were carried out only in the SP-like
domain of PZ. The chymotrypsinogen numbering is used to represent residues of the SP domain, with the N terminus Ile at position 16.
The multiple sequence alignment for Gla, EGF1, and EGF2 domains is the same as our previous PZ paper (Lee et al. 2007) (part of
EGF2 is shown in the alignment). The modified regions are color coded as shown in the legend. (*) Identity, (:) strongly similar.
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simulations of free FVIIa in the same region as PZa (not
shown). A similar bend has been reported and discussed
in the X-ray crystal structures of free FVIIa in this region
(Kemball-Cook et al. 1999; Pike et al. 1999). In our PZa
simulation, the bend occurs near Glu88 at the beginning
of the a-helix between Glu88 and Thr94. As a result,
the region between Gly285 and Gln290 in the protease
domain contacts the EGF1 domain of PZa (with Asn59
and Glu286 forming a strong H-bond). The sequences of
this bending region show no apparent similarities between
PZa and FVIIa; however, this region responds similarly in
both the proteins, with a more prominent bend in PZa.
Another simulation of the PZa structure was carried out
with the Gla and EGF domains held frozen so as to ensure
a more upright orientation of the SP domain relative to
the remainder of the PZa structure (Fig. 2B). It is our
hypothesis that the upright form might approximate the
effect of a putative cofactor (unknown)-bound form of
PZa (similar to the tissue factor-bound form of FVIIa)
with the bent form characteristic of free PZa. The
resemblance of the simulated PZa structure to other
members of the blood coagulation serine protease family
indicates that the in silico design and modeling of PZa
from PZ sequence has reasonably restored serine protease
structural features.
Docking of inhibitors
The PZa model was tested by docking known FVIIa and
FXa inhibitors into the putative active site of PZa. The
primary objective of this docking exercise was to validate
to a reasonable extent the structural morphology of the
PZa active site. AutoDock 3.0.5 (Morris et al. 1998) was
used to perform the docking calculations. In order to
test the scoring function of AutoDock and the adopted
parameters for the inhibitors, we performed unbiased re-
dockings with the unbound 3D structures of both the
receptor (FVIIa, FXa) and the ligand (Supplemental Fig.
S4) and used the known complex structure (X-ray crystal
structure) for evaluating the performance. The idea
behind this was to measure how well the docking
protocol performs when tested against known partners
used in this study. For both FVIIa and FXa, we identified
a near-native structure (within 1.5 Å from the experi-
mental structure) with the top prediction. The top
prediction in each case was the lowest docked energy
pose. The best docked pose for the FVIIa inhibitor had an
RMSD of 0.76 Å relative to the crystal orientation with a
docked energy of 12.06 kcal/mol, while the RMSD
value for FXa inhibitor was 1.21 Å and the docked en-
ergy was 13.75 kcal/mol. Blind docking of the inhibitors
Figure 2. Cartoon representation of the solvent-equilibrated structural model of PZa. (Cyan) Gla domain, (green) EGF1 domain,
(orange) EGF2 domain, (blue) SP domain, (orange spheres) Ca2+ ion, (sticks) Gla, Bha residues, and disulfide bonds. (A) Structure
obtained from unconstrained simulation shows a bend of the SP domain. The Ca distance between Asn59 in the EGF1 domain and
Glu286 in the SP domain is 10.33 Å. Residues Cys131 and Cys234 shown in the figure could be involved in disulfide bond formation,
based on their distance after simulation (Ca distance 8.82 Å). (B) Structure obtained from keeping the Gla and EGF domains fixed,
resulting in a more upright orientation of the SP domain. The figures were prepared using PyMOL (DeLano Scientific).
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from FVIIa and FXa to a region corresponding to the
putative active site of PZa was then carried out. The top-
ranking pose from each case was selected and analysis was
done by visual comparison of the obtained coordinates
relative to the referenced crystallographic coordinates.
One of the important residues in the S1 pocket of
serine proteases is Asp189. The negatively charged side
chain participates in a salt bridge interaction with an
arginine or lysine side chain from the substrate. Small
molecule inhibitors exploit this interaction using an
amidine or a guanidine group of the inhibitor to form
an ion pair with the carboxylate of the aspartate. Initial
docking of the inhibitor into the PZa active site showed
that there were steric clashes that prevented the inhibitor
from forming the salt bridge interaction with Asp189 at
the bottom of the S1 pocket. Studies on serine protease
specificity have shown that apart from the structure of
the active site cleft, the ability of the enzyme to undergo
conformational change to accommodate different sub-
strates via an induced fit mechanism is also important for
broad specificity (Post and Ray 1995). Several studies on
a Met192 mutation in a-lytic protease have found that
the S1 site especially can sample different conformations
and facilitate hydrolysis of many different substrates
(Davis and Agard 1998; Miller and Agard 1999; Ota and
Agard 2001). Keeping this in mind, we performed an
induced minimization of the SP domain of PZa with the
FVIIa inhibitor in the S1 pocket so as to expand the
pocket slightly and eliminate the steric clashes. Residues
that line the S1 binding pocket in PZa are shown in
Figure 3. The fixed structure of PZa after the induced
minimization was then used to dock the FVIIa and FXa
inhibitors.
The docking of the FVIIa inhibitor to PZa (Fig. 4)
shows that the inhibitor binds in a similar orientation to
the PZa binding pocket as to the FVIIa pocket (with a
docked energy of 9.12 kcal/mol), but the salt bridge
interaction with the S1 site Asp189 is slightly weaker
compared with FVIIa (interaction distances larger than for
FVIIa). The inhibitor, however, sits in a similar overall
conformation to FVIIa in the proximal hydrophobic S2
pocket and the distal S3 pocket. The docking of the FXa
inhibitor to PZa shows that the amidine group of the
inhibitor forms the expected salt bridge interaction with
the carboxylate group of Asp189 in the S1 pocket (with a
docked energy of 14.81 kcal/mol), but the overall bind-
ing conformation differs from the X-ray crystal confor-
mation observed for FXa with its inhibitor. The S1 salt
bridge interaction is stronger compared with the FVIIa
inhibitor, but the distal hydrophobic interactions are
different. Overall, it is encouraging that the inhibitor
docking results indicate that several of the binding
characteristics of FVIIa and FXa inhibitor binding are
exhibited by the putative PZa model.
Conclusions
There currently exists a reasonable understanding of the
relationship between sequence and function for blood
coagulation serine proteases. In this study, by employing
computational methods, we have attempted to use existing
knowledge to design a sequence for an activated form of PZ
that could function as a serine protease. Iterative sequence
design, model building, and subsequent simulations have
shown that apart from key structural features, distant struc-
tural elements and residues conserved across the family
also play an important role in maintaining the structure of
the protein. Experimental studies to express and investigate
possible catalytic activity of this sequence could provide
clues toward understanding how evolutionary changes in the
sequence have affected the function of this protein.
Materials and Methods
Design of the PZa sequence
The blood coagulation serine proteases have conserved enzyme
structures and share common structural features of their active
sites. For substrate recognition and catalytic activity, the serine
protease domain must have the following key characteristics
(chymotrypsinogen numbering is used): the His57–Asp102–
Ser195 catalytic triad, a selectivity S1 site composed of
Asp189, Gly216, and Gly226, an oxyanion hole formed by the
backbone NHs of Gly193 and Ser195, a proximal hydrophobic
S2 pocket, a distal hydrophobic S3 pocket, and the salt bridge
between Asp194 and N-terminal residue (Ile16) (Perona and
Craik 1995; Czapinska and Otlewski 1999; Hedstrom 2002).
Figure 3. Catalytic triad region and the residues around the S1 pocket of
solvent-equilibrated PZa (gray). The overall spatial architecture of this
region is similar to FVIIa and FXa. SP domain of FVIIa is overlaid and the
corresponding residues are shown (cyan).
Chandrasekaran et al.
1358 Protein Science, vol. 17
JOBNAME: PROSCI 17#8 2008 PAGE: 5 OUTPUT: Tuesday July 8 00:24:24 2008
csh/PROSCI/164284/ps034801
Fig. 3 live 4/C
In order to identify a reasonable primary sequence for the
activated form of PZ, the multiple sequence alignment of PZ
with FVII, FIX, FX, and PC was used as the starting point (Lee
et al. 2007). The amino acid residues in PZ corresponding to the
key residues (above) that confer these serine protease character-
istics were first modified based on the multiple sequence
alignment. Multiple models were built based on this sequence,
and the best model was subjected to a MD simulation (solvated)
to evaluate the structure of the model, based on its similarity to
SP domains from other blood coagulation factors. This model
was not adequate. Iteration of this procedure, however, led to a
sequence for which, apart from these key residues, all amino
acid residues that were conserved in the other four proteins were
also modified (Fig. 1). This additional sequence modification is
consistent with earlier observations that found that even sub-
stitution of all of the amino acids in the S1 site of trypsin with
their counterparts in chymotrypsin failed to transfer chymo-
trypsin-like characteristics to the variant enzyme (Hedstrom
et al. 1992). Subsequent studies have pointed out that distal
enzyme segments not contacting the substrate are important for
serine protease specificity (Perona and Craik 1997). The N
terminus of the SP domain was chosen based on the minimum
sequence required to form the salt bridge with Asp194 and was
assigned based on FVIIa, since there was no consensus for that
peptide sequence among the coagulation proteins. A total of 32
residues were modified. This new sequence was used to build
the model of the activated form of PZ.
Homology modeling
The overall procedure for the homology modeling was similar to
that employed in a previous study (Lee et al. 2007). A multiple
sequence alignment of human FVIIa, FIXa, FXa, and PC
sequences was created with CLUSTALW, using the BLOSUM
matrices for scoring the alignments (Thompson et al. 1994).
Their corresponding X-ray structures ([PDB entry 1DAN]
[Banner et al. 1996], [1RFN] [Hopfner et al. 1999], [1XKA]
[Kamata et al. 1998], and [1AUT] [Mather et al. 1996],
respectively) were used as structural templates for the homology
modeling. The obtained alignments were checked for insertions
and deletions in the structurally conserved regions and also fine-
tuned manually. The best alignment was selected based on both
the alignment score as well as the reciprocal positions of the
conserved residues in the SP domain. The resulting alignment
was used as an input to construct homology models of PZa using
MODELLER 8v2 (Sali et al. 1995). Residue type and topology
information were added for the two nonstandard residues, Gla
and Bha. Three-dimensional models were built based on a
distance restraint algorithm imposed from the multiple sequence
alignment of the target sequence with the template structures,
applying the CHARMM energy terms. An optimization method
involving conjugate gradients and molecular dynamics with
simulated annealing, available in MODELLER, was employed
to minimize violations of spatial restraints. For the model-
building process, default parameters included in the automodel
class were used, and explicit manual restraints were specified
for disulfide bridges. The model was built as a two-chain system
with 10 disulfide bonds (Res. 18–23, 51–62, 56–71, 73–82, 89–
101, 97–110, 112–125, 164–180, 288–302, and 310–337). To
guarantee sufficient conformational sampling of each active site
residue, an ensemble of 30 models was built, from which the
best final model was selected based on evaluation of stereo-
chemical values from PROCHECK (Laskowski et al. 1993), the
objective function from MODELLER, and by visual inspection.
Figure 4. Lowest docked energy poses of FVIIa and FXa inhibitors. (A) Redocking of FVIIa inhibitor to FVIIa, (B) blind docking of
FVIIa inhibitor to PZa, (C) redocking of FXa inhibitor to FXa, (D) blind docking of FXa inhibitor to PZa. (Orange) Protein side chains
and backbones. Inhibitors are colored by atom type.
Proposed sequence and structure for activated PZ
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The model was also assessed using the Verify3D algorithm
(Bowie et al. 1991; Luethy et al. 1992) to identify any region of
improper folding.
Molecular dynamics (MD) simulation
A stepwise structure refinement approach for the homology
model was performed through MD simulation, to obtain a
solvent-equilibrated model and to remove bad contacts. All
MD simulations were performed using PMEMD9 in the
AMBER9 (Case et al. 2006) suite of molecular modeling
programs. Force field parameters used were taken from the
ff99SB force field included with the AMBER9 molecular
dynamics package. The EGF and Gla domains are based on
the PZ model from our previous study (Lee et al. 2007). The
seven conserved Ca2+ ions in the Gla domain were placed based
on FVIIa X-ray structure, and the additional Ca2+ ions were
placed with malonate coordination (both carboxylates of Gla
involved). The total system was composed of 85,023 atoms
including 12 Ca2+ ions, five Na+ counterions for neutralizing the
system, and 26,502 TIP3P (Jorgensen et al. 1983) water
molecules (solvated in a 12.5 Å layer of water molecules).
Prior to structural equilibration, the model was subjected to
several stages of energy minimization and relaxation. In the first
step, belly dynamics were performed on all the water molecules
and counterions for 25 ps. Belly dynamics involved allowing
motional freedom to the water molecules and the counterions to
relax their positions, while the protein atoms were kept fixed.
This was followed by an energy minimization of all the water
molecules and counterions in 10,000 conjugate gradient steps to
remove steric clashes, while the protein was held fixed. The
whole system was then subjected to minimization, where in the
initial stages of minimization and NPT equilibration phase,
constraints were applied on the backbone atoms of the model
and the H-bond-forming atoms of His57 and Ser195 in the
catalytic triad. A stepwise heating procedure was implemented
over a 35-ps period to bring the system to 300K. In the later
stages of equilibration, the constraints over the backbone atoms
were removed and side chain atom constraints for the catalytic
triad were gradually removed. Equilibration was concluded by
3.5-ns simulations, and these were followed by an unconstrained
production run. Long-range interactions were treated using the
particle mesh Ewald (PME) method (Darden et al. 1993;
Essmann et al. 1995), and a time step of 1.5 fs was used in all
of the molecular dynamics calculations. The stability of the
system and the state of equilibration were followed by monitor-
ing the backbone RMSD and the potential energy of the system.
The final 7.5-ns unconstrained trajectories were used for analysis.
Docking of inhibitors
The flexible ligand docking program AutoDock 3.0.5 (Morris
et al. 1998) was used to dock two known inhibitors, one from
FVIIa (2BZ6) (Groebke et al. 2006) and another from FXa
(1XKA) (Kamata et al. 1998; Supplemental Fig. S1), into the
binding site of modeled PZa, which was fixed. The coordinates
of the protein atoms were obtained by building an average
structure from the final 100 ps of the simulation. The Lamarck-
ian genetic algorithm (GA) was used as the search method, and
grid maps with 61 3 61 3 61 points centered on the ligand with
a grid point spacing of 0.375 Å were computed. The scoring
function in AutoDock is a regression-based method, consisting
of a van der Waals, an electrostatic, a hydrogen-bonding, and a
desolvation energy term, in addition to an entropy term that
accounts for the loss of torsional degrees of freedom upon
binding. For each inhibitor, 50 docking runs were performed
with an initial population of 300, with those differing by <2.0 Å
in positional RMSD being clustered together. Step sizes of 2 Å
for translation and 50° for rotation were chosen, and a maximum
number of 250,000 energy evaluations and 27,000 generations
were considered for each system.
Electronic supplemental material
The following supplemental material is available for this article:
Figure S1: Ramachandran plot of the best homology model
obtained from Modeller;
Figure S2: Verify3D plot of the SP domain coordinates of the
homology model and the corresponding coordinates from the
crystal structures of FVIIa and Fxa;
Figure S3: Plot of backbone RMSD of each domain and all
residues of PZa over 19-nsec MD simulation;
Figure S4: Inhibitors used for docking.
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